

Ludwig Scientist	Affiliation (s)	Session Time	Location	Session Type	Session Track	Presentation/Abstract Title
Saturday, June 2						
Stephen Hodi	Ludwig Harvard	8:00 - 11:30 AM	Hall A, Poster Board: #419a	Poster Session	Genitourinary (Nonprostate) Cancer	Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.
George Demetri	Ludwig Harvard	8:00 –11:30 AM	Hall A, Poster Board: #255	Poster Session	Sarcoma	Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST)
George Demetri	Ludwig Harvard	8:00 –11:30 AM	Hall A, Poster Board: #258	Poster Session	Sarcoma	Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D)
George Demetri	Ludwig Harvard	8:00 –11:30 AM	Hall A, Poster Board: #296	Poster Session	Sarcoma	Targeted tumor profiling and actionable somatic variants in sarcoma
Rakesh Jain	Ludwig Harvard	8:00–11:30 AM	Hall A, Poster Board: #107	Poster Session	Breast Cancer—Metastatic	A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).

*scientist is lead author

**scientist is senior author

Yang Liu	Ludwig Laussane	8:00–11:30 AM	Hall A, Poster Board: #271	Poster Session	Sarcoma	Comprehensive genomic profiling of sarcomas in Chinese population.
Matt Van De Rijn	Ludwig Stanford	8:00 –11:30 AM	Hall A, Poster Board: #288	Poster Session	Sarcoma	CDKN2A deletion as a prognostic marker: A clinico-genomic analysis of sarcoma patients
Maximilian Diehn	Ludwig Stanford	8:00 –9:15 AM	S406	Education Session	Developmental Therapeutics and Translational Research	Liquid Biopsies: Current Uses and Future Directions - Methods and Applications of cfDNA Analysis
Sushama Varma	Ludwig Stanford	8:00 –11:30 AM	Hall A, Poster Board: #308	Poster Session	Sarcoma	Discovery and characterization of novel, recurrent, targetable ALK fusions in leiomyosarcoma
Ralph Weichselbaum	Ludwig Chicago	9:30 AM - 12:00 PM	Hall B1	Opening Session	Special Sessions	Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture
Sandro Santagata	Ludwig Harvard	1:15 - 2:30 PM	S100bc	Education Session	Central Nervous System Tumors Clinical Trials Developmental Therapeutics and Translational Research	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice
Jedd Wolchok	Ludwig MSK	1:15 - 2:30 PM	S100a	Education Session	Special Sessions	ASCO/Radiological Society of North America (RSNA) Joint Session: Assessing Response and Progression With Targeted Therapy and Immunotherapy - Immune-Related Response and RECIST in Radiographic Imaging
Stephen Hodi	Ludwig Harvard	1:15 - 4:45 PM	Hall A, Poster Board: #169	Poster Session	Central Nervous System Tumors	Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort

*scientist is lead author

**scientist is senior author

Joshua Cohen	Ludwig John Hopkins	1:15 - 4:45 PM	Hall A, Poster Board #61	Poster Session	Head and Neck Cancer	Cisplatin (CIS) versus cetuximab (CET) with definitive concurrent radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC): An analysis of veteran's health data.
Joshua Cohen	Ludwig John Hopkins	1:15 - 4:45 PM	Hall A, Poster Board #338	Poster Session	Health Services Research, Clinical Informatics, and Quality of Care	Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (aNSCLC).
Margaret Callahan**	Ludwig MSK	3:00 - 6:00 PM	Hall B1	Oral Abstract Session	Developmental Therapeutics—Immunotherapy	ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
Margaret Callahan	Ludwig MSK	3:00 - 6:00 PM	Hall B1	Oral Abstract Session	Developmental Therapeutics—Immunotherapy	Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.
Ravindra Majeti, Irving L. Weissman	Ludwig Stanford	3:00 - 6:00 PM	Hall B1	Oral Abstract Session	Developmental Therapeutics—Immunotherapy	A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
Stephen Hodi	Ludwig Harvard	1:15 - 4:45 PM	E451, Poster Board #169	Poster Discussion Session	Central Nervous System Tumors	Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort
Sunday, June 3						
Rakesh Jain	Ludwig Harvard	8:00–11:30 AM	Hall A, Poster Board #305	Poster Session	Gastrointestinal (Noncolorectal) Cancer	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.

*scientist is lead author

**scientist is senior author

Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein	Ludwig John Hopkins	8:00–11:30 AM	Hall A, Poster Board #9	Poster Session	Gastrointestinal (Colorectal) Cancer	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).
Yang Liu	Ludwig Laussane	8:00-11:30 AM	Hall A, Poster Board #241	Poster Session	Gastrointestinal (Noncolorectal) Cancer	Comparison of clinical outcome and safety after minimally invasive esophagectomy: Ivor Lewis versus McKeown—A real-world multicenter observational study from China.
Taha Merghoub	Ludwig MSK	8:00–11:30 AM	Hall A, Poster Board #327b	Poster Session	Gastrointestinal (Noncolorectal) Cancer	A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).
Kristen Aufiero Ramirez, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus**	Ludwig New York	8:00–11:30 AM	Hall A, Poster Board: #428b	Poster Session	Lung Cancer—Non-Small Cell Metastatic	Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).
Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein	Ludwig John Hopkins	11:30 AM – 12:45 PM	Hall D2, Poster Board #9	Poster Discussion Session	Gastrointestinal (Colorectal) Cancer	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).
Monday, June 4						
Stephen Hodi	Ludwig Harvard	8:00 - 11:30 AM	Hall A, Poster Board: #250	Poster Session	Developmental Therapeutics—Immunotherapy	Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.
Benjamin Izar*, Stephen Hodi	Ludwig Harvard	8:00 - 11:30 AM	Hall A, Poster Board: #288	Poster Session	Developmental Therapeutics—Immunotherapy	Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.

*scientist is lead author

**scientist is senior author

Stephen Hodi	Ludwig Harvard	8:00 - 11:30 AM	Hall A, Poster Board: #228	Poster Session	Developmental Therapeutics—Immunotherapy	Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.
Stephen Hodi	Ludwig Harvard	8:00 - 11:30 AM	Hall A, Poster Board: #315a	Poster Session	Developmental Therapeutics—Immunotherapy	Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalized medicine
Bianca Santomasso, Margaret Callahan**	Ludwig MSK	8:00 - 11:30 AM	Hall A, Poster Board: #298	Poster Session	Developmental Therapeutics—Immunotherapy	Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade.
Michael Postow**	Ludwig MSK	8:00 - 11:30 AM	Hall A, Poster Board: #309	Poster Session	Developmental Therapeutics—Immunotherapy	Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.
Michael Postow, Jedd Wolchok**	Ludwig MSK	8:00 - 11:30 AM	Hall A, Poster Board: #227	Poster Session	Developmental Therapeutics—Immunotherapy	Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
Matt Van De Rijn, Maximilian Diehn, Ash Alizadeh	Ludwig Stanford	8:00 – 11:30 AM	Hall A, Poster Board: #209	Poster Session	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA.
Stephen Hodi	Ludwig Harvard	11:30 - 12:45 AM	Hall B1, Poster Board: #228	Poster Discussion Session	Developmental Therapeutics—Immunotherapy	Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.
Michael Postow, Jedd Wolchok**	Ludwig MSK	11:30 - 12:45 AM	Hall B1, Poster Board: #227	Poster Discussion Session	Developmental Therapeutics—Immunotherapy	Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

*scientist is lead author

**scientist is senior author

Ralph Weichselbaum	Ludwig Chicago	1:15 – 4:45 PM	Hall A, Poster Board: #252	Poster Session	Gynecologic Cancer	A phase 1/2A trial of synthetic DNA vaccine immunotherapy targeting HPV-16 and -18 after chemoradiation for cervical cancer.
Benjamin Izar	Ludwig Harvard	1:15 – 4:45 PM	Hall A, Poster Board: #386	Poster Session	Melanoma/Skin Cancers	Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFM): Implications for combination with immunotherapy.
Benjamin Izar	Ludwig Harvard	1:15 – 4:45 PM	Hall A, Poster Board: #408	Poster Session	Melanoma/Skin Cancers	Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance
Stephen Hodi, Jedd Wolchok	Ludwig Harvard	1:15 – 4:45 PM	Hall A, Poster Board: #343	Poster Session	Melanoma/Skin Cancers	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001
Margaret Callahan, Michael Postow, Jedd Wolchok**	Ludwig MSK	1:15 – 4:45 PM	Hall A, Poster Board: #388	Poster Session	Melanoma/Skin Cancers	Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma.
Stephane Pourpe, Hyejin Choi, Taha Merghoub, Jedd Wolchok**	Ludwig MSK	1:15 – 4:45 PM	Hall A, Poster Board: #173	Poster Session	Immunobiology	Exploring effects of MEK inhibition in tumor microenvironment in non-small cell lung cancer (NSCLC) pre-clinical models.
Teresa Rasalan, Dmitriy Zamarin, Phillip Wong	Ludwig MSK	1:15 – 4:45 PM	Hall A, Poster Board: #280	Poster Session	Gynecologic Cancer	A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.
Dmitriy Zamarin	Ludwig MSK	1:15 – 4:45 PM	Hall A, Poster Board: #258	Poster Session	Gynecologic Cancer	The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer.

*scientist is lead author

**scientist is senior author

Jedd Wolchok, Michael Postow**	Ludwig MSK	1:15 – 4:45 PM	Hall A, Poster Board: #379	Poster Session	Melanoma/Skin Cancers	Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.
Michael Postow*, Danielle McCabe, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus	Ludwig MSK; Ludwig New York	1:15 – 4:45 PM	Hall A, Poster Board: #377	Poster Session	Melanoma/Skin Cancers	Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma.
Anthony Letai	Ludwig Harvard	4:30–6:00 PM	E450	Clinical Science Symposium	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant	Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).
Stephen Hodi, Jedd Wolchok	Ludwig Harvard	1:15 – 4:45 PM	E451, Poster Board #343	Poster Discussion Session	Melanoma/Skin Cancers	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001
Publication-only Abstracts						
Muriel Laine*, Marianne Greene, Ya-Fang Chang, Geoffrey Greene**	Ludwig Chicago	N/A	N/A	Publication-only abstracts	Breast Cancer—Metastatic	Lasofoxifene efficacy in a mammary intraductal (MIND) xenograft model of ERα+ breast cancer.
Rakesh Jain	Ludwig Harvard	N/A	N/A	Publication-only abstracts	Gastrointestinal (Noncolorectal) Cancer	Angiotensin system inhibitors during induction chemotherapy for esophageal adenocarcinoma: Analysis of survival.
Joshua Cohen	Ludwig John Hopkins	N/A	N/A	Publication-only abstracts	Healthy Services Research, Clinical Informatics, and Quality of Care	Cost-effectiveness of adjuvant chemotherapy in early stage breast cancer.

*scientist is lead author

**scientist is senior author

Joshua Cohen, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein	Ludwig John Hopkins	N/A	N/A	Publication-only abstracts	Gastrointestinal (Noncolorectal) Cancer	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.
Yang Liu	Ludwig Laussane	N/A	N/A	Publication-only abstracts	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	A real-world observational study to explore clinical characteristics of Chinese patients with T1 non-small cell lung cancer complicated with lymph metastases.
Yang Liu	Ludwig Laussane	N/A	N/A	Publication-only abstracts	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	Surgical treatments of Chinese patients with lung malignant tumors.
Matthew Vander Heiden	Ludwig MIT	N/A	N/A	Publication-only abstracts	Gastrointestinal (Noncolorectal) Cancer	Association between changing body composition after diagnosis and survival of patients with advanced pancreatic cancer.
Michael Postow*, Jedd Wolchok	Ludwig MSK	N/A	N/A	Publication-only abstracts	Tumor Biology	Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors.
Michael Postow, Margaret Callahan, Jedd Wolchok	Ludwig MSK	N/A	N/A	Publication-only abstracts	Melanoma/Skin Cancers	Multigene sequencing, copy number alteration detection, and survival with first-line PD-1 based therapy in patients with mucosal melanoma.
Jedd Wolchok, Margaret Callahan	Ludwig MSK	N/A	N/A	Publication-only abstracts	Developmental Therapeutics—Immunotherapy	Safety of influenza vaccination in patients undergoing immunotherapy treatment for advanced cancer.
Margaret Callahan	Ludwig MSK	N/A	N/A	Publication-only abstracts	Patient and Survivor Care	Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors.

*scientist is lead author

**scientist is senior author

Michael Postow, Margaret Callahan, Jedd Wolchok	Ludwig MSK	N/A	N/A	Publication-only abstracts	Melanoma/Skin Cancers	Multigene sequencing, copy number alteration detection, and survival with first-line PD-1 based therapy in patients with mucosal melanoma.
Kanika Arora, Taha Merghoub	Ludwig MSK	N/A	N/A	Publication-only abstracts	Melanoma/Skin Cancers	Clonal evolution of uveal melanoma metastases.
Danny Khalil	Ludwig MSK	N/A	N/A	Publication-only abstracts	Healthy Services Research, Clinical Informatics, and Quality of Care	Total parenteral nutrition utilization in metastatic cancer patients: A nationwide 10-year analysis from 2006 to 2015.
Michael Postow, Mary Macri, Ralph Venhaus, Jedd Wolchok	Ludwig MSK; Ludwig New York	N/A	N/A	Publication-only abstracts	Developmental Therapeutics—Immunotherapy	Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.

*scientist is lead author

**scientist is senior author